Insmed Inc (INSM)

[smallinvestor]

As discussed earlier, I don't, repeat, DON't view this deal being the best INSM could come up with. (Of course, INSM will probably open above $2 in the morning) I would rather see a 10% royalty to all indications rather than 4% to shut out DNA/TRCA from opt-in, and keep Iplex on the shortstature market.

Reasons:

1. We did give up short stature to TRCA. (giving up certainty.) of course it's peanuts compared to others, but there is also an uncertainly surrounding other indications as I have mentioned in the other posts. Essentially, DNA/TRCA put INSM back to a PII company with much larger potentials.

2. The opt-in options to both DNA and TRCA is like saying: DNA and Tercica each Reserves the right to merge with INSM as equal partners, the discretion is not INSM's.

Positives that come out of this:

3. no damages, and 4% royalty...

Overall, better than no deal, but on a scale of 1-10, 10 being the greatest deal INSM can come up with, it's between 4-6 in my book.